Table 1.
Comparison of Selected Drugs in Terms of a Response
| Agent | Splenomegaly1 | Anemia2 | Symptoms3 | References |
|---|---|---|---|---|
|
IMiDs |
|
|
|
|
|
Thalidomide |
19 % |
43 % |
NS |
[15] |
| (Celgene Corp., Summit, NJ, USA) |
8 % |
22 % |
NR |
[16] |
|
Lenalidomide |
10 % |
19 % |
NR |
[48] |
| (Celgene Corp., Summit, NJ, USA) |
42 % |
30 % |
NR |
[18] |
|
Pomalidomide |
0 |
≤40 % |
NR |
[21] |
| (Celgene Corp., Summit, NJ, USA) |
11 % |
37 % |
NR |
[22] |
| 0 |
17 % |
NR |
[23] |
|
|
JAK Inhibitors |
|
|
|
|
|
Ruxolitinib (INCB018424) |
44 % |
14 % |
52–82 % |
[42] |
| (Incyte Corporation, Wilmington, DE, USA—US rights; Novartis AG, Basel, Switzerland—ex-US rights) |
42 %4 |
NR |
46 %5 |
[43] |
| 32 %5 |
NR |
NR |
[44] |
|
|
SAR302503 (TG101348) (Sanofi, Paris, France) |
39 % |
0 |
25–89 % |
[47] |
|
CYT387 (Cytopia/YM Biosciences, Mississauga, Ontario, Canada) |
45 |
50 % |
NR |
[49] |
|
Pacritinib (SB1518) (S*Bio Pte Ltd, Singapore) |
44 % |
<1 % |
NR |
[50] |
|
Lestaurtinib (CEP-701) (Cephalon, Frazer, PA, USA) |
18 % |
1 % |
NR |
[51] |
|
mTOR Inhibitor |
|
|
|
|
| Everolimus (RAD001) (Novartis AG, Basel, Switzerland) | 17 % | <1 % | 69 %5 | [52] |
IMiDs = immunomodulatory drugs; NR = not reported; NS = not significant.
1Percentage of patients achieving ≥50 % reduction in spleen size, unless otherwise specified.
2Percentage of patients achieving a ≥2 g/dL increase in Hb, unless otherwise specified.
3Percentage of patients achieving complete resolution of symptoms.
4Percentage of patients achieving ≥35 % reduction in spleen volume.
5Percentage of patients achieving ≥50 % reduction in total symptom score on the Myelofibrosis Symptom Assessment Form.